The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
1. A substantially purified or recombinant polypeptide comprising a fragment of an amino acid sequence of SEQ ID NO: 2886, wherein said fragment comprises 10 or more consecutive amino acids from said amino acid sequence.
2. The substantially purified or the recombinant polypeptide of claim 1 wherein the substantially purified or the recombinant polypeptide is immunogenic.
3. The substantially purified or the recombinant polypeptide of claim 2 further comprising a pharmaceutically acceptable carrier.
4. The substantially purified or the recombinant polypeptide of claim 3 further comprising an adjuvant.
5. The substantially purified or the recombinant polypeptide of claim 1 wherein the fragment comprises 12 or more consecutive amino acids from said amino acid sequence.
6. The substantially purified or the recombinant polypeptide of claim 1 wherein the fragment comprises 14 or more consecutive amino acids from said amino acid sequence.
7. The substantially purified or the recombinant polypeptide of claim 1 wherein the fragment comprises 16 or more consecutive amino acids from said amino acid sequence.
8. The substantially purified or the recombinant polypeptide of claim 1 wherein the fragment comprises 18 or more consecutive amino acids from said amino acid sequence.
9. The substantially purified or the recombinant polypeptide of claim 1 wherein the fragment comprises 20 or more consecutive amino acids from said amino acid sequence.